Category - Markets

BTIG raised its price target for KalVista Pharmaceuticals (NASDAQ:KALV) to $27 from $18 after the company inked a multifaceted collaboration with Merck (NYSE:MRK) last week. The stock closed at $9.74 on Oct. 13...

BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million. The offering is expected to close on Oct. 17. BioTime also granted...

William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5. “Continued clinical catalysts and a clear development path with the company’s...

Canaccord Genuity initiated coverage of Heska (NASDAQ:HSKA) with a “buy” rating and price target of $115. The stock closed at $91.38 on Oct. 4. “Our survey work and checks suggest ongoing attractive market trends in...

Maxim Group raised its price target for Abeona Therapeutics (NASDAQ:ABEO) to $35 from $17, citing advances in the gene therapy space and comparatives to competitor, AveXis. “Given the valuation gap between these two...

Maxim Group upgraded Celsion (NASDAQ:CLSN) to “buy” from “hold” with a $7 price target after the company renegotiate outstanding warrants, raising $15.6-million. Shares of Celsion were quoted at $4.96, down $1.09, or...

H.C. Wainwright initiated coverage of Myomo (NYSE MKT:MYO) with a “buy” rating and $12 price target. The stock closed at $6 on Sept. 29. Myomo is a wearable robotics company targeting a largely unmet need in providing a...

William Blair upgraded Zogenix (NASAQ:ZGNX) to “outperform” and Stifel more than doubled its price target to $55 from $26 after the company unveiled strongly positive Phase 3 data for ZX008 (fenfluramine) in Dravet...

Maxim Group raised its price target for BeiGene (NASDAQ:BGNE) to $120 from $77 after the company announced preliminary data from its ongoing Phase 1/2 study of BGB-A317 (PD-1 antibody) in Chinese patients with advanced...

Paradigm Capital launched coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with a “buy” rating and price target of $2.25. The stock closed at 95 cents on Sept. 27. Profound is commercializing the TULSA-PRO medical...